AVS Bio Expands Capabilities in Antibody Discovery and Protein Production with Acquisition of ImmunoPrecise Antibodies Europe

AVS Bio, a global provider of bioprocessing inputs and services, has acquired ImmunoPrecise Antibodies Europe B.V. to enhance its antibody discovery and protein production capabilities in Europe. The acquisition strengthens AVS Bio's service portfolio for the biologics and pharmaceutical industries, positioning it as a comprehensive partner for biotech and pharmaceutical firms developing next-generation therapeutics.

Norwich, CT -- Arlington Capital Partners, a Washington, D.C.-area private investment firm specializing in government-regulated industries, announced that its portfolio company AVS Bio has acquired ImmunoPrecise Antibodies Europe B.V. (IPA Europe), a leading provider of antibody discovery and protein production services in Europe. The acquisition, which strengthens AVS Bio's service portfolio in the biologics and pharmaceutical sectors, was completed on August 6, 2025.

IPA Europe, based in Utrecht and Oss, the Netherlands, offers a comprehensive suite of antibody discovery, engineering, and characterization services. The company's expertise in recombinant protein expression and scalable protein production for both research and pre-clinical applications makes it a valuable addition to AVS Bio's growing service portfolio. With this acquisition, AVS Bio aims to enhance its capabilities in antibody discovery and protein production, positioning itself as a comprehensive partner for biotechnology and pharmaceutical firms developing next-generation therapeutics.

AVS Bio, headquartered in Norwich, CT, is a global provider of specific pathogen-free (SPF) laboratory products and services that support the development and manufacture of vaccines, therapeutics, and biologics. The company supplies leading manufacturers with critical bioprocessing inputs including SPF eggs, antigens, and antibodies, and also offers diagnostic testing and GMP support services. AVS Bio operates over 20 facilities across North America and Europe and is a portfolio company of Arlington Capital Partners.

The acquisition of IPA Europe reflects AVS Bio's strategic commitment to grow through both organic investment and targeted mergers and acquisitions (M&A). Jac Price, CEO of AVS Bio, commented, "IPA Europe brings exceptional technical capabilities and a reputation for scientific rigor that aligns perfectly with our mission to support customers from early discovery through commercial manufacturing. This acquisition significantly enhances our service offering and geographic reach, and we’re excited to welcome the IPA Europe team into the AVS Bio family."

Malcolm Little, a Partner at Arlington Capital Partners, added, "This acquisition reflects AVS Bio’s strategic commitment to grow through both organic investment and targeted M&A. IPA Europe is a natural fit, offering complementary capabilities in antibody discovery and recombinant protein manufacturing that will accelerate AVS Bio’s expansion into the upstream biologics R&D value chain. This transaction marks a key milestone in AVS Bio’s broader strategy to build a diversified biologics services platform serving the therapeutic innovation markets."

Ilse Roodink and Roland Romijn, General Managers of IPA Europe, commented, "We’re thrilled to join forces with AVS Bio. Their platform offers immediate opportunities for us to scale our operations, invest in next-generation technologies, and better serve our clients with an end-to-end continuum of biologics development capabilities."

Arlington has an extensive track record of building leading companies in highly regulated industries that are critical to healthcare infrastructure, government systems, and national security. Within healthcare, Arlington focuses on working with businesses that save lives, improve the delivery of products and services, and reduce costs for patients and providers. Other notable recent healthcare sector investments the firm has made include Afton Scientific, Everest Clinical Research, Grand River Aseptic Manufacturing, Millstone Medical Outsourcing, Riverpoint Medical, and TEAM Technologies.

Edgemont Partners served as exclusive sell-side advisor to ImmunoPrecise Antibodies Ltd. in connection with the transaction.

References:
[1] https://www.stocktitan.net/news/IPA/avs-bio-an-arlington-capital-partners-portfolio-company-expands-t9qa850fik3r.html
[2] https://theoutpost.ai/news-story/chai-discovery-secures-70-m-for-ai-driven-molecular-discovery-in-drug-development-18826/